Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AbbVie | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: AbbVie

HUMIRA sales up 11% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie

4Q Revenues: $5.5 billion (+7%) 

4Q Loss: $810 million (earnings were $1.1 billion 4Q13)

FY Revenues: $20.0 billion (+6%)

FY Earnings: $1.8 billion (earnings were $4.1 billion FY13)

Comments: Growth in the quarter was driven primarily by HUMIRA sales, up 11% to $3.4 billion. Creon sales were $151 million, up 31%. Dyslipidemia sales were $104 million, up 14%. Synagis sales were down 5% to 298 million in the quarter. AndroGel sales declined 20% to $230 million. Earnings were impacted the Shire termination. R&D expenses were $879 million in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters